Assembly, activation, and physiologic influence of the plasma kallikrein/kinin system

International Immunopharmacology

Volumn 8, Issue 2, 2008, Pages 161-165

  Schmaier, Alvin H ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Bradykinin; Bradykinin B2 receptor; Factor XII; High molecular weight kininogen; Prekallikrein; Prolylcarboxypeptidase

Indexed keywords

BLOOD CLOTTING FACTOR 12; BRADYKININ B2 RECEPTOR; HIGH MOLECULAR WEIGHT KININOGEN; KALLIKREIN; KININ; PREKALLIKREIN; PROLINE CARBOXYPEPTIDASE;

ARTERY THROMBOSIS; ARTICLE; BLOOD CLOTTING; CELL SURFACE; GENE DELETION; HEMOSTASIS; HUMAN; IN VIVO STUDY; KALLIKREIN KININ SYSTEM; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; RISK FACTOR; SURFACE CHARGE; THROMBOCYTE; THROMBOGENESIS; THROMBUS;

ANIMALS; FACTOR XII; HUMANS; KALLIKREIN-KININ SYSTEM; RECEPTOR, BRADYKININ B2; THROMBOSIS;

EID: 37549039054     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2007.08.022     Document Type: Article

References (57)

1. Sainz I.M., Pixley R.A., and Colman RA. Fifty years of research on the plasma kallikrein-kinin system: from protein structure and function to cell biology and in-vivo pathophysiology. Thromb Haemost 98 (2007) 77-83
2. Gailani D., and Renne T. The intrinsic pathway of coagulation: a target for treating thromboembolic disease. J Thromb Haemost 5 (2007) 1106-1112
3. Motta G., Rojkjaer R., Hasan A.A.K., Cines D.B., and Schmaier A.H. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: a novel mechanism for contact activation. Blood 91 (1998) 516-528
4. Shariat-Madar Z., Mahdi F., and Schmaier A.H. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem 277 (2002) 17962-17969
5. Gustafson E.G., Schutsky D., Knight L., and Schmaier A.H. High molecular weight kininogen binds to unstimulated platelets. J Clin Invest 78 (1986) 310-318
6. Gustafson E.J., Schmaier A.H., Wachtfogel Y.T., Kaufman N., Kucich U., and Colman R.W. Human neutrophils contain and bind high molecular weight kininogen. J Clin Invest 84 (1989) 28-35
7. Schmaier A.H., Kuo A., Lundberg D., Murray S.C., and Cines D.B. Expression of high molecular weight kininogen on human umbilical vein endothelial cells. J Biol Chem 263 (1988) 16327-16333
8. Reddigari S.R., Shibayama Y., Brunnee T., and Kaplan A.P. Human Hageman factor (factor XII) and high molecular weight kininogen compete for the same binding site on human umbilical vein endothelial cells. J Biol Chem 268 (1993) 11982-11987
9. Shariat-Madar Z., Mahdi F., and Schmaier A.H. Factor XI assembly and activation on human umbilical vein endothelial cells in culture. Thromb Haemost 85 (2001) 544-551
10. Herwald H., Dedio J., Kellner R., Loos M., and Muller-Esterl W. Isolation and characterization of the kininogen binding protein p33 from endothelial cells. J Biol Chem 271 (1996) 13040-13047
11. Joseph K., Ghebrehiwet B., Peerschke E.I.B., Reid K.B.M., and Kaplan A.P. Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: identity with the receptor that binds to the globular "heads" of C1q (qC1qR). Proc Natl Acad Sci 93 (1996) 8552-8557
12. Colman R.W., Pixley R.A., Najamunnisa S., Yan W., Wang J., Mazar A., et al. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. J Clin Invest 100 (1997) 1481-1487
13. Hasan A.A.K., Zisman T., and Schmaier A.H. Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells. Proc Natl Acad Sci 95 (1998) 3615-3620
14. Zhang J.-C., Donate F., Qi X., Ziats N.P., Juarez J.C., Mazar A.P., et al. The antiangiogenic activity of cleaved high molecular weight kininogen is mediated through binding to endothelial cell tropomyosin. Proc Natl Acad Sci 99 (2002) 12224-12229
15. Mahdi F., Shariat-Madar Z., Figueroa C.D., and Schmaier A.H. Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin on endothelial cell membranes. Blood 99 (2002) 3585-3596
16. Renne T., Dedio J., David G., and Muller-Esterl W. High molecular weight kininogen utilizes heparin sulfate proteoglycans for accumulation on endothelial cells. J Biol Chem 275 (2000) 33688-33695
17. Renne T., Schuh K., and Muller-Esterl W. Local bradykinin formation is controlled by glycosaminoglycans. J Immunol 175 (2005) 3377-3385
18. Fernando L.P., Fernando A.N., Joseph K., and Kaplan A.P. Assessment of the role of heparan sulfate in high molecular weight kininogen binding to human umbilical vein endothelial cells. J Thromb Haemost 1 (2003) 2444-2449
19. Mahdi F., Shariat-Madar Z., and Schmaier A.H. The relative priority of prekallikrein and factors XI/XIa assembly on cultured endothelial cells. J Biol Chem 278 (2003) 43983-43990
20. Ho D.H., Badellino K., Baglia F.A., Sun M.F., Zhao M.M., Gailani D., et al. The role of high molecular weight kininogen and prothrombin as cofactors in the binding of factor XI A3 domain to the platelet surface. J Biol Chem 275 (2000) 25139-25145
21. Yun T.H., Baglia F.A., Myles T., Navaneetham D., Lopez J.A., Walsh P.N., et al. Thrombin activation of factor XI on activates platelets requires the interaction of factor XI and platelet glycoprotein Ib alpha with thrombin anion-binding exosites I and II, respectively. J Biol Chem 278 (2003) 48112-48119
22. Mandle R.J., Colman R.W., and Kaplan A.P. Identification of prekallikrein and high molecular weight kininogen complexes in plasma. Proc Natl Acad Sci 73 (1976) 4179-4183
23. Loza J.P., Gurevich V., Johnstone M., and Pannell R. Platelet-bound prekallikrein promotes pro-urokinase-induced clot lysis: a mechanism for targeting the factor XII dependent intrinsic pathway of fibrinolysis. Thromb Haemost 71 (1994) 347-352
24. Motta G., Shariat-Madar Z., Mahdi F., Sampaio C.A.M., and Schmaier A.H. Assembly and activation of high molecular weight kininogen and prekallikrein on cell matrix. Thromb Haemost 86 (2001) 840-847
25. Lin Y., Harris R.B., Yan W., and Colman R.W. High molecular weight kininogen peptides inhibit formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation. Blood 90 (1997) 690-697
26. Rojkjaer R., Hasan A.A.K., Motta G., Schousboe I., and Schmaier A.H. Factor XII does not initiate prekallikrein activation on endothelial cells. Thromb Haemost 80 (1998) 74-81
27. Han E.D., MacFarlane R.C., Mulligan A.N., Scafidi J., and Davis III A.E. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 109 (2002) 1057-1063
28. Iwaki T., and Castellino F.J. Plasma levels of bradykinin are suppressed in factor XII-deficient mice. Thromb Haemost 95 (2006) 1003-1010
29. Yang H.Y.T., Erdos E.G., Chiang T.S., Jenssen T.A., and Rogers J.G. Characterization of an enzyme that inactivates angiotensin II (angiotensinase C). Biochem Pharmacol 19 (1970) 1201-1211
30. Oyda C.E., Marinkovic D.V., Hammon K.J., Stewart T.A., and Erdos E.G. Purification and properties of prolylcarboxypeptidase (Angiotensinase C) from human kidney. J Biol Chem 253 (1978) 5927-5931
31. Shariat-Madar Z., Mahdi F., and Schmaier A.H. Recombinant prolylcarboxypeptidase activates plasma prekallikrein. Blood 103 (2004) 4554-4561
32. Moreira C.R., Schmaier A.H., Mahdi F., da Motta G., Nader H.B., and Shariat-Madar Z. Identification of prolylcarboxppeptidase as the cell matrix-associated prekallikrein activator. FEBS Lett 523 (2002) 167-170
33. Kumamoto K., Stewart T.A., Johnson A.R., and Erdos EG. Prolylcarboxypeptidase (angiotensinase C) in human lung and cultured cells. J Clin Invest 67 (1981) 210-215
34. Jackman H.L., Tan F., Schraufnagel D., Dragovic T., Dezso B., Becker R.P., et al. Plasma membrane-bound and lysosomal peptidases in human alveolar macrophages. Am J Respir Cell Mol Biol 13 (1995) 196-204
35. Skarnes W.C. Gene trapping methods for the identification and functional analysis of cell surface proteins in mice. Method Enzymol 328 (2000) 592-615
36. Biederbick A., Rose S., and Elsasser H.-P. A human intracellular apyrase-like protein, LALP70, localizes to lysosomal/autophagic vacuoles. J Cell Sci 112 (1999) 2473-2484
37. McCarthy J.J., Meyer J., Moliterno D.J., Newby L.K., Rogers W.J., and Topol E.J. GenQuest multicenter study. Evidence for substantial effect modification by gender in a large scale genetic association study of the metabolic syndrome among coronary heart disease patients. Hum Genet 114 (2003) 87-98
38. Wang L., Feng Y., Zhang Y., Zhou H., Jiang S., Niu T., et al. Prolylcarboxypeptidase gene, chronic hypertension, and risk of preeclampsia. Am J Obstet Gynecol 195 (2006) 162-171
39. Shariat-Madar Z., Rahimi E., Mahdi F., and Schmaier A.H. Over-expression of prolylcarboxypeptidase enhances plasma prekallikrein activation on Chinese hamster ovary cells. Am J Physiol Heart Circ Physiol 289 (2005) H2697-H2703
40. Shariat-Madar Z., Mahdi F., Warnock M., Homeister J.W., Srikanth S., Krijanovski Y., et al. Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin. Blood 108 (2006) 192-199
41. Abadir P.M., Periasamy A., Carey R.M., and Siragy H.M. Angiotensin II type 2 receptor-bradykinin B2 receptor functional heterodimerization. Hypertension 48 (2006) 316-322
42. Munoz C.M., and Leeb-Lundberg L.M. Receptor-mediated internalization of bradykinin. DDT1 MF-2 smooth muscle cells process internalized bradykinin via multiple degradative pathways. J Biol Chem 267 (1992) 303-309
43. Schmaier A.H. The kallikrein-kinin and renin angiotensin systems have a multilayered interaction. Am J Physiol REgul Integr Comp Physiol 285 (2003) R1-R13
44. Groger M., Lebesgue D., Pruneau D., Relton J., Kim S.-W., Nussberger J., et al. Release of bradykinin and expression of kinin B2 receptors in the brain: role for cell death and brain edema formation after focal cerebral ischemia in mice. J Cereb Blood Flow Metab 25 (2005) 978-989
45. Xia C.-F., Smith R.S., Shen B., Yang Z.-R., Borlongan C.V., Chao L., et al. Postischemic brain injury is exacerbated in mice lacking the kinin B2 receptor. Hypertension 47 (2006) 752-761
46. Renne T., Pozgajova M., Gruner S., Schuh K., Pauer H.U., Burfeind P., et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 280 (2005) 28572-28580
47. Colman R.W. Is the plasma kallikrein-kinin system antithrombotic?. Blood 108 (2006) 1
48. Soria J.M., Almasy L., Souto J.C., Bacq D., Buil A., Faure A., et al. A quantitative-trait locus in the human factor XII gene influences both plasma factor XII levels and susceptibility to thrombotic disease. Am J Hum Genet 70 (2002) 567-574
49. Zito F., Lowe G.D.O., Rumley A., McMahon A.D., and Humphries S.E. Association of the factor XII 46C > T polymorphism with risk of coronary heart disease in the WOSCOPS study. Atherosclerosis 165 (2002) 153-158
50. Colhoun H.M., Zito F., Chan N.N., Rubens M.B., Fuller J.H., and Humphries S.E. Activated factor XII levels and factor XII 46C > T genotype in relation to coronary artery calcification in patients with type 1 diabetes and healthy subjects. Atherosclerosis 163 (2002) 363-369
51. Roldan V., Corral J., Marin F., Pineda J., Vicente V., and Gonzalez-Conejero R. Synergistic association between hypercholesterolemia and the C46T factor XII polymorphism for developing premature myocardial infraction. Thromb Haemost 94 (2005) 1294-1299
52. Cooper J.A., Miller G.J., Bauer K.A., Morrissey J.H., Meade T.W., and Howarth D.J. Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation 102 (2000) 2816-2822
53. Grundt H., Nilsen D.W., Hetland O., Valente E., and Fagertun H.E. Activation of factor XIIa2 (FXIIa) predicts recurrent coronary events after an acute myocardial infarction. Am Heart J 147 (2004) 260-266
54. Kleinschnitz C., Stoll G., Bendszuz M., Schuh K., Pauer H.U., Burfeind P., et al. Targeting coagulation factor XII provides protection from pathologic thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 203 (2006) 513-518
55. Renne T., Nieswandt B., and Gailani D. The intrinsic pathway of coagulation is essential for thrombus stability in mice. Blood Cells Mol Dis 36 (2006) 148-151
56. Smith S.A., Mutch N.J., Baskar D., Rohloff P., Docampo R., and Morrissey J.H. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci U S A 103 (2006) 903-908
57. Kannemeier C., Shibamiya A., Nakazawa F., Trusheim H., Ruppert C., Markart P., et al. Proc Natl Acad Sci 104 (2007) 6388-6393